Please login to the form below

Not currently logged in
Email:
Password:

HER2 inhibitor

This page shows the latest HER2 inhibitor news and features for those working in and with pharma, biotech and healthcare.

UK approval for Seagen’s oral HER2 inhibitor Tukysa

UK approval for Seagen’s oral HER2 inhibitor Tukysa

metastatic breast cancer who have previously received at least two anti-HER2 treatment regimens. ... The oral HER2 inhibitor is also approved in the US for the treatment of HER2-positive advanced cancer.

Latest news

  • Seattle Genetics wins FDA priority review for oral HER2 drug Seattle Genetics wins FDA priority review for oral HER2 drug

    If approved will compete with AZ/Daiichi Sankyo's Enhertu. Seattle Genetics has scored a US Food and Drug Administration (FDA) priority review for its oral HER2 inhibitor tucatinib in breast ... If Seattle does gain approval for tucatinib, it will go on

  • AZ, Daiichi Sankyo get early okay for DS-8201, now named Enhertu AZ, Daiichi Sankyo get early okay for DS-8201, now named Enhertu

    The US regulator has cleared the HER2 inhibitor drug – now known as Enhertu (trastuzumab deruxtecan) – for metastatic HER2-positive disease in patients who have previously been treated with two or more ... s chemotherapy Xeloda (capecitabine) in

  • AZ, Daiichi Sankyo strengthen case for HER2 candidate AZ, Daiichi Sankyo strengthen case for HER2 candidate

    Kadcyla is the smallest in terms of sales in Roche’s HER2 franchise, with its sales falling behind those of Herceptin (trastuzumab) and Perjeta (pertuzumab). ... Also looking to encroach on the HER2 market is Seattle Genetics, with its orally-active

  • Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day

    It’s due for first regulatory verdicts in 2021. Pevonedistat (TAK-924) for HR-MDS: Pevonedistat is a selective NEDD8 activating enzyme (NAE) inhibitor being developed as a cancer treatment, initially ... TAK-788 for non-small cell lung cancer:Phase 1/2

  • Seattle Genetics preps filing next year for oral HER2 drug Seattle Genetics preps filing next year for oral HER2 drug

    Company has positive phase 3 data to support filings. Seattle Genetics has positive phase 3 data in hand for its orally-active HER2 inhibitor tucatinib in breast cancer that the company ... on the massive success of Roche’s HER2 franchise, which

More from news
Approximately 2 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Acquisition company. 628. Cascadian Therapeutics/Seattle Genetics. Lead programme tucatinib, oral, small molecule TKI highly selective for HER2 (p2). ... Royalty monetisation. 230. Jiangsu Hengrui Medicine/Arcutis. SHR0302, selective JAK inhibitor, for

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    440. OncoEthix / Merck &Co. Lead product oral BET inhibitor, OTX015 for oncology indications (p1b). ... ONT-380 (ARRY-380), oral, reversible and selective small molecule HER2 inhibitor (p1).

  • Pharma deals during April 2014 Pharma deals during April 2014

    GSK's recently approved MEK inhibitor Mekinist and BRAF inhibitor Tafinlar will position Novartis to become a leader in the potential blockbuster market for metastatic melanoma, neglected by their current portfolio. ... Additional GSK products include

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...
Why empathy in digital patient recruitment is vital
This is where empathy mapping can be incredibly effective....
Top 10 ways that Medical Affairs teams can leverage the Impetus InSite Platform®
Some of the most popular and innovative ways of using our cutting-edge asynchronous and synchronous virtual tools for Medical Affairs teams....